Today CureVac announced financial results for the third quarter and first nine months of 2024 as well as shared business updates, including details on the next indications we’re pursuing in both oncology and infectious disease. Press release:

We are gearing up for the 12th Annual @mrnaconference in Boston this upcoming week!.#ICYMI: Learn more about the presentations and posters we’ll be sharing while there in our recent press release: #mRNA2024 #mRNA

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

Today we’ve announced our upcoming poster presentations at the @sitcancer 39thAnnual Meeting. You can find more information in our press release here: . #SITC24 #Glioblastoma #CancerVaccine #mRNA #EndCancer

We were pleased to collaborate with @moderna_tx , @BioNTech_Group and @PharmaLexGLOBAL in authoring What’s in a word – Defining “gene therapy medicines”, just published in the @ASGCTherapy journal Molecular Therapy Methods & Clinical Development. #mRNA.

Excited to share the first data from our Phase 1 study in glioblastoma, presented today at #ESMO2024! The ability of CVGBM to generate new immune responses underscores the potential of our #mRNA technology in the fight against #cancer.

There’s one day left before the start of #ESMO2024! CureVac will be presenting on the very first clinical data from the Phase 1 study of our mRNA-based #cancervaccine candidate CVGBM and will also have poster session. Learn more below!

We’re excited to see @GSK has announced positive Phase 2 headline data from the #seasonalinfluenza #mRNA program which we fully licensed to them under terms of our licensing agreement earlier this summer. Find more information in the CureVac press release:

We’re pleased to announce we will be presenting the first data from our ongoing Phase 1 CVGBM #cancervaccine study at the @myESMO Congress 2024. You can find more details in our press release here:. #ESMO24 #mRNA #CancerVaccines #CancerResearch

Today CureVac announced financial results for the second quarter and first half of 2024 as well as business updates, including the part B start of our ongoing Phase 1 study of cancer vaccine candidate CVGBM. Learn more here:

We are pleased to welcome two new members to our Supervisory Board: recently appointed Birgit Hofmann and – announced today – Dr. Mehdi Shahidi. Please find more information on Dr. Shahidi’s appointment in today’s release:

🌐 Update on Trial Dates from CureVac! 🌐. Today, we announced new trial dates for our ongoing patent litigation against Pfizer/BioNTech in the U.S., alongside related proceedings in Germany and the UK. Read the full Press Release here:

Today we share two important announcements: a licensing agreement with our long-time partner GSK which will support us to enter our next chapter, and restructuring plans that, while a difficult decision, will position us better for the future. #mRNA

🌟 Meet Manuel Göpferich, Bioinformatician-Data Engineer from CureVac, at The European mRNA Conference 2024 in Frankfurt! 🌟.Manuel will be discussing the Design of Optimised UTR Sequences Using Support Vector Machines.

🌟 Back-to-back excitement awaits as we gear up for the Goldman Sachs 45th Annual Global Healthcare Conference in Miami today! 🌟.Join us for another round of insightful discussions and networking opportunities alongside industry stalwarts and investment enthusiasts.

At EACR 2024, we will be showcasing our approaches in oncology, the next frontier for mRNA technology. Our team has been working tirelessly to advance our unique platform in this field, and we’re excited to share our findings with the scientific community.

Delighted to share that Dominik Vahrenhorst, Associate Director Computational Biology at CureVac, will be a chair & speaker at Computational RNA Design & Delivery Summit, taking place in Boston from June 4-6. Find out more:

Following our encouraging interim Phase 2 data in our Seasonal Influenza Program, we've started a new Phase 2 study to assess targeted optimizations of multivalent vaccine candidate for improved immune responses against the influenza B strain. Read more:

Yesterday CureVac announced financial results for the first quarter of 2024 as well as business updates. Read more:

Very happy CureVac could participate with a scientific contribution at the CIMT (Europe’s Cancer Immunotherapy Meeting), which took place May 15-17, 2024 in Mainz! Let's keep the momentum going!.Find out more about the meeting here: #CIMT2024 #mRNA.

Today CureVac announced financial results for the fourth quarter and full year of 2023 as well as business updates. CureVac continues to make great strides in evolving the business. Read more: